{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"31"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"Discontinuation of investigational product due to toxicity","groups":[{"description":"NGM120 30mg Subcutaneous Injection","id":"OG000","title":"Part 1 NGM120 30mg"},{"description":"NGM120 100mg Subcutaneous Injection","id":"OG001","title":"Part 1 NGM120 100mg"},{"description":"NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).","id":"OG002","title":"Part 2 NGM120 30mg"},{"description":"NGM120 100mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).","id":"OG003","title":"Part 2 NGM120 100mg"},{"description":"Placebo Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).","id":"OG004","title":"Part 2 Placebo"},{"description":"NGM120 100 mg Subcutaneous Injection","id":"OG005","title":"Part 3 NGM120 100mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set","reportingStatus":"POSTED","timeFrame":"From enrollment to end of treatment up to 24 months","title":"To Determine the Safety and Tolerability of NGM120","type":"PRIMARY","unitOfMeasure":"Participants"}